Research graph
References from Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdy275 · 2018 · External reference
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)
10.1097/jto.0000000000000033 · 2014 · External reference
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers
10.1371/journal.pone.0028204 · 2011 · External reference
Acquired resistance to TKIs in solid tumours: learning from lung cancer
10.1038/nrclinonc.2014.104 · 2014 · External reference
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
10.1158/2159-8290.cd-14-0337 · 2014 · External reference
Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdq189 · 2010 · External reference
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation
10.1007/s00280-011-1632-x · 2011 · External reference
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
10.1007/s12094-015-1297-8 · 2015 · External reference
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
10.1200/jco.2011.41.2056 · 2012 · External reference
Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor failure in non-small cell lung cancer patients with EGFR mutations
10.4143/crt.2014.244 · 2015 · External reference
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
10.1056/nejmoa1411817 · 2015 · External reference
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
10.1016/s1470-2045(16)30508-3 · 2016 · External reference
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
10.1200/jco.2016.70.3223 · 2017 · External reference
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies
10.1002/cncr.31891 · 2019 · External reference
Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
10.1056/nejmoa1612674 · 2017 · External reference
Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
10.2217/fon-2020-0203 · 2020 · External reference
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: a retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma
10.1111/1759-7714.13378 · 2020 · External reference
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
10.1007/s00432-018-2754-x · 2018 · External reference
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
10.1016/j.lungcan.2018.11.037 · 2019 · External reference
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer
10.2217/fon-2019-0324 · 2019 · External reference
Intercalated treatment following rebiopsy is associated with a shorter progression-free survival of osimertinib treatment
10.4143/crt.2017.460 · 2018 · External reference
Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial
10.1016/j.ejca.2021.02.019 · 2021 · External reference
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
10.1056/nejmoa1713137 · 2018 · External reference
Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
10.1056/nejmoa1913662 · 2020 · External reference
Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset
10.1016/j.jtho.2018.09.004 · 2019 · External reference
Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: a real-world data analysis
10.3892/ol.2020.11801 · 2020 · External reference
CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)
10.1200/jco.2018.77.9363 · 2018 · External reference
